Capricor Therapeutics Inc CAPR

US Biotechnology

$3.85 ▼ -8.11% ($-0.34)

🔥 High Short Interest 🗓️ Earnings Next Week

Open $4.04

Prev Close $4.19

Day Range $3.80 – $4.66

52W Range $2.96 – $40.37

Market Cap $222.96M

Beta 0.42

EPS (TTM) $-2.31

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2002-06-04
Shares Out.	57,910,000
Website	capricor.com/ ↗
Phone	13026587581
Employees	231
Net Income	-$33.9M
Free Cash Flow	-$112.9M
Total Assets	$326.3M
Total Liabilities	$47.6M
Equity	$278.7M

About Capricor Therapeutics Inc

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics Inc is a publicly traded company under the ticker symbol CAPR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.